Pharmactive Biotech Products S.L.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharmactive Biotech Products S.L. - overview
Established
2009
Location
Madrid, -, Spain
Primary Industry
Biotechnology
About
Based in Madrid, Spain, and established in 2009, Pharmactive Biotech Products S. L. engages in the research, development, manufacturing, and distribution of natural ingredients to industries including nutraceutical, pharmaceutical, and veterinary. Jean-Marie Raymond is the chief executive officer (CEO) and founder of the company with laboratories and manufacturing plants operating in Madrid, Spain as of 2021.
In June 2021, Pharmactive Biotech Products S. L. was acquired by Siparex. The company provides natural plant-based ingredients such as saffron and black garlic for the food supplement industry.
Pharmactive Biotech Products S. L. offers premium branded ingredients including Affron for mood improvement, ABG+ for cardiovascular health, AffronEYE intended for eye health, Liboost for sexual performance, and Olivactive that strengthen the immune system naturally. Following the acquisition in June 2021, Pharmactive Biotech Products S.
L. will partner with Siparex to accelerate its development plans through external growth and expand its portfolio of natural ingredients as well as the company's international commercial presence.
Current Investors
Siparex
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.pharmactive.eu
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Pharmactive Biotech Products S.L. - timeline of key events
Pharmactive Biotech Products S.L. - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,271,849.4 | 4,660,971 | 5,555,266.8 | 6,008,538.9 | 8,782,475.7 | 11,299,129.6 | - | - | - |
| % Revenue Growth (YoY) | - | (11.6%) | 19.2% | 8.2% | 46.2% | 28.7% | - | - | - |
| EBITDA (USD) | 541,686 | 520,982.5 | 465,710.4 | 1,034,807.6 | 2,545,948.7 | 3,752,507.1 | - | - | - |
| Operating Income (USD) | 538,699.9 | 493,543.2 | 424,436.7 | 966,715.4 | 2,466,830 | 3,643,913.3 | - | - | - |
| Operating Margin | 10.2% | 10.6% | 7.6% | 16.1% | 28.1% | 32.2% | - | - | - |
| % EBITDA Margin | 10.3% | 11.2% | 8.4% | 17.2% | 29.0% | 33.2% | - | - | - |
| NET Income (USD) | 395,741.3 | 595,345 | 368,706.1 | 767,478.1 | 1,919,708.3 | 2,934,086.2 | - | - | - |
| % Net Margin | 7.5% | 12.8% | 6.6% | 12.8% | 21.9% | 26.0% | - | - | - |
Pharmactive Biotech Products S.L. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Pharmactive Biotech Products S.L. | - |
Displaying 1 - 1 of 1
Pharmactive Biotech Products S.L. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.